Mitsui to Participate in KIFMEC Specific Purpose Company

Aug. 18, 2014

Main Contents

Mitsui & Co., Ltd. ("Mitsui", Head Office: Tokyo, President and CEO: Masami Iijima) has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). It is planned to start leasing its building to KIFMEC from September 2014.

Hyogo prefecture has been nominated as National Strategic Special Zone with an aim to promote advanced medical technology and services through the integration and collaboration among healthcare providers, R&D institutions, and manufactures.
KIFMEC will start its operation in November 2014, as a hospital that provides highly advanced medical treatment and service in liver disease and gastroenterology treatments in Kobe's Port Island which under government, industry and academic collaborations, aims to accumulate advanced medical Technology and services.
KIFMEC has appointed Dr. Koichi Tanaka, Professor Emeritus at Kyoto University as its chairman, with an aspiration to play a pivotal role in Kobe's Bio-medical innovation cluster as the international base of advanced medical technology such as living donor liver transplant surgery, and endoscopic and laparoscopic treatments.
Dr. Tanaka is active globally and is also our partner in Sing-Kobe Liver Transplant Centre Pte. Ltd. (Mitsui 49%, "SKLTC"), a clinic specializing in the treatment of liver disease and living donor liver transplant surgery, which opened in Singapore in September, 2013.

Mitsui as the shareholder of "KIFMEC specific purpose company" will support the operation of KIFMEC and its global expansion. Mitsui will align with SKLTC and utilize IHH Healthcare Bhd., ("IHH")'s network, the largest healthcare network in Asia which Mitsui invested in 2011, to introduce Japan's highly advanced medical treatment and services to the Asian region in order to contribute to the globalization of Japan's healthcare industry and to the advancement of medical treatment in Asia.

1. Outline of KIFMEC specific purpose company

Name KIFMEC specific purpose company
Head Office Chuo-ku, Kobe, Hyogo, Japan
Establishment June 15, 2012
Representative Tadahiko Tanizawa
Equity Approx. ¥1,800 mil.
Shareholders Mitsui 40.6%, Others 59.4%
Business Activities Operations relating to acquisition, management and sales of a hospital building based on Asset Securitization Plan

2. Outline of KIFMEC

Name Kobe International Frontier Medical Centre
Head Office Chuo-ku, Kobe, Hyogo, Japan
Establishment April 1, 2013
Representative Koichi Tanaka
Description A highly anticipated medical center in Asia that will provide advanced medical services in gastroenterology and liver disease
Clinical Specialties Gastroenterology, Gastroenterological Surgery, Endoscopic Surgery, Transplant Surgery, Oncology, Radiology, Clinical Pathology, Laboratory Medicine, Anesthesiology
Number of Beds 120 (including 6 intensive care units)

KIFMEC Rendering

KIFMEC Rendering

3. Project Scheme

Project Scheme

This announcement contains forward-looking statements. These forward-looking statements are based on Mitsui's current assumptions, expectations and beliefs in light of the information currently possessed by it and involve known and unknown risks, uncertainties and other factors. Such risks, uncertainties and other factors may cause Mitsui's actual results, financial position or cash flows to be materially different from any future results, financial position or cash flows expressed or implied by these forward-looking statements. These risks, uncertainties and other factors referred to above include, but are not limited to, those contained in Mitsui's latest Annual Securities Report and Quarterly Securities Report, and Mitsui undertakes no obligation to publicly update or revise any forward-looking statements.
This announcement is published in order to publicly announce specific facts stated above, and does not constitute a solicitation of investments or any similar act inside or outside of Japan, regarding the shares, bonds or other securities issued by us.


For inquiries on this matter, please contact

Mitsui & Co., Ltd.
Corporate Communications Division
Tomomi Taura
Telephone: +81-3-3285-6645
Facsimile: +81-3-3285-9819